Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8362651 | 1.00 | POLB (0.34) | POLBHCRTR1HCRTR2CA1CA2 | |
| SCHEMBL3870481 | 1.00 | POLB (0.34) | POLBHCRTR1HCRTR2CA1CA2 | |
| Hydrochloric Acid SCHEMBL3870061 | 0.98 | POLB (0.33) | POLBHCRTR1HCRTR2CA1CA2 | |
| Hydrochloric Acid SCHEMBL3870064 | 0.98 | POLB (0.33) | POLBHCRTR1HCRTR2CA1CA2 | |
| SCHEMBL8292292 | 0.78 | POLB (0.32) | POLB | |
| SCHEMBL13827635 | 0.76 | POLB (0.40) | POLBHCRTR1HCRTR2CA1CA2 | |
| SCHEMBL469197 | 0.76 | POLB (0.40) | POLBHCRTR1HCRTR2CA1CA2 | |
| SCHEMBL5385277 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL5385281 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL5460270 | 0.74 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1682524-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | disclosed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005040142-A9 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | AVENTIS PHARMA INC (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005040142-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| CN-1585757-A | Oligopeptides and compositions containing them as cathepsin S inhibitors | AVENTIS PHARMA INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | POLB 2078/4885HCRTR1 2282/4885HCRTR2 2940/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | POLB 2078/4885HCRTR1 2282/4885HCRTR2 2940/4885 |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885HCRTR1 2232/4885HCRTR2 3025/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | POLB 1980/4885HCRTR1 2175/4885HCRTR2 3216/4885 |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885HCRTR1 2232/4885HCRTR2 3025/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 2141/4885HCRTR1 2142/4885HCRTR2 2773/4885 |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | POLB 736/4885HCRTR1 3384/4885HCRTR2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.